Online inquiry

IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4791MR)

This product GTTS-WQ4791MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets DPP4 gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001379604.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1803
UniProt ID P27487
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4791MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14243MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ376MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ2163MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ1783MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ14893MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ9062MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ6900MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ10974MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW